In tandem with Enhertu’s inclusion in China’s national insurance program, Daiichi Sankyo is planting a foothold in local ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation ...

Toshinori Agatsuma, head of research at Daiichi Sankyo, has died. He led development of ADC technology behind breast cancer ...

The new 1.1 billion-yuan ($152 million) production facility in Shanghai will make antibody-drug conjugates, which use ...

Daiichi Sankyo Company is making significant strides in the pharmaceutical industry, evidenced by its financial growth and strategic collaborations, such as with Merck on MK-6070. The company is set ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...

The UK’s National Institute for Health and Care Excellence (NICE) has once again rejected Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu (trastuzumab deruxtecan), marking the third ...

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...

Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca (NASDAQ:AZN)'s ENHERTU that showed clinically meaningful responses across a broad range of tumorsENHERTU now has... BASKING RIDGE ...